Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA
On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration hosted a two-day virtual meeting, Advancing Psychedelic Clinical Study Design.
The below commentary, written by Psychedelic Alpha’s Josh Hardman, is certainly not exhaustive, but rather aims to share a selection of observations from the event. It’s ordered broadly chronologically.
This second issue covers Day 2 of the meeting. If you haven’t already, you can read Day 1 coverage here.
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In